TrialHaemophilia : the official journal of the World Federation of Hemophilia2021

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.

Midori Shima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.